T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy

Biochimica et Biophysica Acta - General Subjects

Volumn 1840, Issue 1, 2014, Pages 378-386

  Jamnani, Fatemeh Rahimi ^a   Rahbarizadeh, Fatemeh ^b   Shokrgozar, Mohammad Ali ^a   Mahboudi, Fereidoun ^a   Ahmadvand, Davoud ^c,d   Sharifzadeh, Zahra ^a   Parhamifar, Ladan ^d,e   Moghimi, S Moein ^d,e  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chimeric antigen receptor; HER2; Oligoclonal T cell therapy; Single domain antibodies (VHH)

Indexed keywords

ANTIBODY; CAMELID SINGLE DOMAIN ANTIBODY; CD134 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; CELL ENGINEERING; CELL FUNCTION; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL;

CAMELIDAE;

3,3′,5,5′-TETRAMETHYL BENZIDINE; CAR; CDR; CHIMERIC ANTIGEN RECEPTOR; COMPLEMENTARITY DETERMINING REGION; HCAB; HEAVY-CHAIN ANTIBODIES; HER2; IPTG; ISOPROPYL-Β-D-THIO-GALACTOSIDE; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; OLIGOCLONAL T CELL THERAPY; SINGLE DOMAIN ANTIBODIES (VHH); T CELL RECEPTOR; TAG 72; TCR; TMB; TUMOR ASSOCIATED GLYCOPROTEIN 72; VARIABLE DOMAIN OF CAMEL HEAVY-CHAIN ANTIBODY; VHH; VHH-CAR; VHH-CHIMERIC ANTIGEN RECEPTOR;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; NEOPLASMS; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84885337140     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.09.029     Document Type: Article

References (49)

1. A. Barber, K.R. Meehan, and C.L. Sentman Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells Gene Ther. 18 2011 509 516
2. F.R. Jamnani, F. Rahbarizadeh, M.A. Shokrgozar, D. Ahmadvand, F. Mahboudi, and Z. Sharifzadeh Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells Exp. Cell Res. 318 2012 1112 1124
3. N.P. Restifo, M.E. Dudley, and S.A. Rosenberg Adoptive immunotherapy for cancer: harnessing the T cell response Nat. Rev. Immunol. 12 2012 269 281
4. K.J. Curran, H.J. Pegram, and R.J. Brentjens Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions J. Gene. Med. 14 2012 405 415
5. T.S. Park, S.A. Rosenberg, and R.A. Morgan Treating cancer with genetically engineered T cells Trends Biotechnol. 29 2011 550 557
6. Y. Nakazawa, L.E. Huye, V.S. Salsman, A.M. Leen, N. Ahmed, L. Rollins, G. Dotti, S.M. Gottschalk, M.H. Wilson, and C.M. Rooney PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor Mol. Ther. 19 2011 2133 2143
7. D. Chinnasamy, Z. Yu, M.R. Theoret, Y. Zhao, R.K. Shrimali, R.A. Morgan, S.A. Feldman, N.P. Restifo, and S.A. Rosenberg Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice J. Clin. Invest. 120 2010 3953 3968
8. M. Sadelain, R. Brentjens, and I. Riviere The basic principles of chimeric antigen receptor design Cancer Discov. 3 2013 388 398
9. M.V. Maus, and C.H. June Zoom zoom: racing CARs for multiple myeloma Clin. Cancer Res. 19 2013 1917 1919
10. G. Lipowska-Bhalla, D.E. Gilham, R.E. Hawkins, and D.G. Rothwell Targeted immunotherapy of cancer with CAR T cells: achievements and challenges Cancer Immunol. Immunother. 61 2012 953 962
11. D.E. Gilham, R. Debets, M. Pule, R.E. Hawkins, and H. Abken CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe Trends Mol. Med. 18 2012 377 384
12. A. Hombach, A.A. Hombach, and H. Abken Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response Gene Ther. 17 2010 1206 1213
13. D.M. Kofler, M. Chmielewski, G. Rappl, A. Hombach, T. Riet, A. Schmidt, A.A. Hombach, C.M. Wendtner, and H. Abken CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation Mol. Ther. 19 2011 760 767
14. V. Hoyos, B. Savoldo, C. Quintarelli, A. Mahendravada, M. Zhang, J. Vera, H.E. Heslop, C.M. Rooney, M.K. Brenner, and G. Dotti Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 24 2010 1160 1170
15. A.A. Hombach, and H. Abken Young T cells age during a redirected anti-tumor attack: chimeric antigen receptor-provided dual costimulation is half the battle Front. Immunol. 4 2013 135
16. S.R. Riddell, M.C. Jensen, and C.H. June Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond Biol. Blood Marrow Transplant. 19 2013 S2 S5
17. S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, S.R. Rheingold, D.T. Teachey, A. Chew, B. Hauck, J.F. Wright, M.C. Milone, B.L. Levine, and C.H. June Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 2013 1509 1518
18. M. Radic Armed and accurate: engineering cytotoxic T cells for eradication of leukemia BMC Biotechnol. 12 2012 6
19. B.G. Till, M.C. Jensen, J. Wang, X. Qian, A.K. Gopal, D.G. Maloney, C.G. Lindgren, Y. Lin, J.M. Pagel, L.E. Budde, A. Raubitschek, S.J. Forman, P.D. Greenberg, S.R. Riddell, and O.W. Press CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results Blood 119 2012 3940 3950
20. A.A. Hombach, J. Heiders, M. Foppe, M. Chmielewski, and H. Abken OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells Oncoimmunology 1 2012 458 466
21. M.A. Pule, K.C. Straathof, G. Dotti, H.E. Heslop, C.M. Rooney, and M.K. Brenner A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Mol. Ther. 12 2005 933 941 (Pubitemid 41614489)
22. S. Wilkie, G. Picco, J. Foster, D.M. Davies, S. Julien, L. Cooper, S. Arif, S.J. Mather, J. Taylor-Papadimitriou, J.M. Burchell, and J. Maher Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor J. Immunol. 180 2008 4901 4909
23. A.A. Hombach, and H. Abken Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling Int. J. Cancer 129 2011 2935 2944
24. V. Russo, A. Bondanza, F. Ciceri, M. Bregni, C. Bordignon, C. Traversari, and C. Bonini A dual role for genetically modified lymphocytes in cancer immunotherapy Trends Mol. Med. 18 2012 193 200
25. S. Gattenlohner, A. Marx, B. Markfort, S. Pscherer, S. Landmeier, H. Juergens, H.K. Muller-Hermelink, I. Matthews, D. Beeson, A. Vincent, and C. Rossig Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor Cancer Res. 66 2006 24 28 (Pubitemid 43166003)
26. F.J. Iri-Sofla, F. Rahbarizadeh, D. Ahmadvand, and M.J. Rasaee Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase Exp. Cell Res. 317 2011 2630 2641
27. S. Khaleghi, F. Rahbarizadeh, D. Ahmadvand, M.J. Rasaee, and P. Pognonec A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells Int. J. Hematol. 95 2012 434 444
28. Z. Sharifzadeh, F. Rahbarizadeh, M.A. Shokrgozar, D. Ahmadvand, F. Mahboudi, F.R. Jamnani, and S.M. Moghimi Genetically Engineered T Cells Bearing Chimeric Nanoconstructed Receptors Harboring TAG-72-Specific Camelid Single Domain Antibodies as Targeting Agents Cancer Lett. 334 2012 237 244
29. J.A. Kolkman, and D.A. Law Nanobodies - from llamas to therapeutic proteins Drug Discovery Today: Technol. 7 2010 139 146
30. F. Rahbarizadeh, F. Rahimi jamnani, and F.J. Iri-Sofla Nanobody, new agent for combating against breast cancer cells E. Gunduz, M. Gunduz, Breast Cancer - Current And Alternative Therapeutic Modalities 2011 InTech Rijeka 347 370
31. E. Sadeqzadeh, F. Rahbarizadeh, D. Ahmadvand, M.J. Rasaee, L. Parhamifar, and S.M. Moghimi Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells J. Control. Release 156 2011 85 91
32. D. Ahmadvand, M.J. Rasaee, F. Rahbarizadeh, R.E. Kontermann, and F. Sheikholislami Cell selection and characterization of a novel human endothelial cell specific nanobody Mol. Immunol. 46 2009 1814 1823
33. B. Dalby, S. Cates, A. Harris, E.C. Ohki, M.L. Tilkins, P.J. Price, and V.C. Ciccarone Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications Methods 33 2004 95 103 (Pubitemid 38569654)
34. R.I. Mahato, J. Henry, A.S. Narang, O. Sabek, D. Fraga, M. Kotb, and A.O. Gaber Cationic lipid and polymer-based gene delivery to human pancreatic islets Mol. Ther. 7 2003 89 100 (Pubitemid 36305362)
35. J.D. Beatty, B.G. Beatty, and W.G. Vlahos Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay J. Immunol. Methods 100 1987 173 179 (Pubitemid 17085455)
36. J. Sharon, M.A. Liebman, and B.R. Williams Recombinant polyclonal antibodies for cancer therapy J. Cell. Biochem. 96 2005 305 313 (Pubitemid 41437863)
37. J.S. Haurum Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov. Today 11 2006 655 660
38. J. Haurum, and S. Bregenholt Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle IDrugs 8 2005 404 409 (Pubitemid 40613994)
39. T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis Proc. Natl. Acad. Sci. U. S. A. 106 2009 3294 3299
40. W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, and M. Hasmann Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res. 69 2009 9330 9336
41. J.B. Spangler, J.R. Neil, S. Abramovitch, Y. Yarden, F.M. White, D.A. Lauffenburger, and K.D. Wittrup Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling Proc. Natl. Acad. Sci. U. S. A. 107 2010 13252 13257
42. G.M. Giordano Attianese, V. Marin, V. Hoyos, B. Savoldo, I. Pizzitola, S. Tettamanti, V. Agostoni, M. Parma, M. Ponzoni, M.T. Bertilaccio, P. Ghia, A. Biondi, G. Dotti, and E. Biagi In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor Blood 117 2011 4736 4745
43. J.R. Park, D.L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H.B. Meechoovet, C. Bautista, W.C. Chang, J.R. Ostberg, and M.C. Jensen Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol. Ther. 15 2007 825 833 (Pubitemid 46432004)
44. A.A. Hombach, M. Chmielewski, G. Rappl, and H. Abken Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation Hum. Gene Ther. 24 2013 259 269
45. D.M. Davies, and J. Maher Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells Arch. Immunol. Ther. Exp. 58 2010 165 178 (Warsz)
46. R.D. Guest, R.E. Hawkins, N. Kirillova, E.J. Cheadle, J. Arnold, A. O'Neill, J. Irlam, K.A. Chester, J.T. Kemshead, D.M. Shaw, M.J. Embleton, P.L. Stern, and D.E. Gilham The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens J. Immunother. 28 2005 203 211 (Pubitemid 40593985)
47. M. Chmielewski, A. Hombach, C. Heuser, G.P. Adams, and H. Abken T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity J. Immunol. 173 2004 7647 7653 (Pubitemid 39628207)
48. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol. Ther. 18 2010 843 851
49. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol. Ther. 18 2010 666 668